144 ·Filed Apr 8, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001950047-26-003332
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual sale execution via future Form 4 filings; while routine, the sale by a director may signal reduced conviction ahead of potential catalysts. Given the relatively small size relative to company's $1.8B market cap, immediate market impact is likely limited.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
PHVS ▲ +22.72% at T+60d
NEUTRAL call ✓ call won +22.72% · α vs SPY +11.94% · entry $27.07 → $33.22
Entry anchored
Apr 8, 03:59 PM ET
via exchange tick
T+1d
-1.63%
call -1.63% · α -1.56%
$26.63
settled 6mo ago
T+5d
+6.32%
call +6.32% · α +3.13%
$28.78
settled 6mo ago
T+20d
+11.23%
call +11.23% · α +3.66%
$30.11
settled 5mo ago
T+60d
+22.72%
call +22.72% · α +11.94%
$33.22
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Berndt Modig, a director and officer of Pharvaris N.V., filed a Form 144 to notify of intent to sell up to 23,333 common shares acquired through vested restricted stock units. The sale is planned on the NASDAQ exchange, with proceeds to be handled through Morgan Stanley Smith Barney.

Key Facts

  • Reporting person: Berndt B.A.E. Modig, Director and Officer of Pharvaris N.V.
  • Number of shares proposed for sale: 23,333 common shares
  • Shares were acquired upon vesting of restricted stock units between 05/31/2025 and 03/12/2026
  • Filing date: April 8, 2026
  • Broker: Morgan Stanley Smith Barney LLC
  • No specific price or total value disclosed in filing

Financial Impact

Approximately $2.3 million based on current market price (~$100/share), though exact value depends on sale timing

insider ownershippotential share dilutionmarket sentiment

Risk Factors

  • Perception of insider selling could weigh on investor sentiment, especially if no follow-on purchases are made
  • Timing relative to upcoming earnings or clinical trial readouts is unknown

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-003332
Document: 0001950047-26-003332-index.html0001950047-26-003332
Document: 0001950047-26-003332.txt0001950047-26-003332
37 reports for PHVS
Performance horizon
90% Hit rate 9 of 10 directional calls best @ T+60▲ +21.31%Mar 20, 2026
Filters
Rows
Reports for PHVS — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$38.06 $36.37▲ +4.44%▲ +5.26%$31.07 (+18.38%)
Sep 14, 2026
17d ago
144
NEUTRAL ★ 2/10
$38.06 $35.20▼ −7.51%▼ −9.63%$31.07 (−18.38%)
Sep 14, 2026
18d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.86 $36.02▼ −7.31%▼ −7.41%$31.07 (−20.06%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.02 $36.37▼ −4.34%▼ −4.12%$31.07 (−18.29%)
Sep 8, 2026
24d ago
6-K
BULLISH ★ 8/10
$37.84 $38.86▲ +2.70%▲ +3.36%$31.07 (−17.90%)
Aug 12, 2026
7w ago
6-K
NEUTRAL ★ 6/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 12, 2026
7w ago
Press Release
BULLISH ★ 7/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 6, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$34.45 $34.04▼ −1.19%▼ −2.40%$31.07 (−9.83%)
Jul 6, 2026
12w ago
Press Release
BULLISH ★ 6/10
$33.22 $35.07▲ +5.57%▲ +5.08%$31.07 (−6.49%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$33.86 $35.96▲ +6.20%▲ +5.27%$31.07 (−8.25%)
Showing 10 of 37

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access